144 Participants NeededMy employer runs this trial

AVA6103 for Cancer

Recruiting at 1 trial location
AC
Overseen ByAvacta Clinical Team
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.

Are You a Good Fit for This Trial?

Inclusion Criteria

I have pancreatic ductal adenocarcinoma (PDAC).
I am 18 years old or older.
4. Has a life expectancy of ≥3 months, in the opinion of the investigator.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase 1a Dose Escalation

Participants receive escalating doses of AVA6103 in two schedules: Day 1 of a 21-day cycle (Q3W) and Day 1 of a 14-day cycle (Q2W) until disease progression, unacceptable toxicities, withdrawal, or death.

Variable, based on individual response

Phase 1b Dose Expansion

Participants receive AVA6103 at the recommended phase 2 dose until disease progression, unacceptable toxicities, withdrawal, or death.

Variable, based on individual response

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of adverse events and survival outcomes.

Up to 30 days after last dose

What Are the Treatments Tested in This Trial?

Interventions

  • AVA6103

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Group I: AVA6103 Phase 1b Dose ExpansionExperimental Treatment1 Intervention
Group II: AVA6103 Phase 1a Dose Escalation Q3WExperimental Treatment1 Intervention
Group III: AVA6103 Phase 1a Dose Escalation Q2WExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Avacta Life Sciences Ltd

Lead Sponsor

Trials
1
Recruited
160+